DUBLIN, Ireland – With its $960 million cash-and-shares acquisition of Elan Drug Technologies (EDT) slated to close in the current quarter, Alkermes Inc. spent Monday afternoon bringing analysts and investors up to speed on how to model the soon-to-be-enlarged company and on where to look for the double-digit growth it has set its sights on. (BioWorld International) Read More
